Immunofluorescence analysis of cerebral microvascular density in APP/PS1 mice

PRIMARY OUTCOME

cerebral microvascular density and average vessel length

EXPECTED OUTCOMES

1. The intervention targeting the nominated disease mechanism shifts cerebral microvascular density and average vessel length in the predicted direction relative to the matched control arm. 2. Secondary disease-relevant readouts in Alzheimer's disease remain directionally concordant with the primary endpoint rather than showing isolated single-assay effects. 3. The effect persists after adjustment for baseline covariates, batch effects, or repeated-measures structure used in the study design.

SUCCESS CRITERIA

- Prespecified primary endpoint (cerebral microvascular density and average vessel length) improves versus control with p < 0.05 or an equivalent corrected threshold used by the study. - The effect size is biologically meaningful and reproduced across technical/biological replicates or the validation subset. - Safety, data quality, and missingness remain within protocol-defined bounds so the result is interpretable rather than driven by attrition or assay failure.

PROTOCOL

1. Establish 1-month-old APP/PS1 mice and wild-type controls cohorts for Alzheimer's disease and predefine inclusion, exclusion, and quality-control criteria before intervention. 2. Apply the experimental manipulation described for the nominated disease mechanism, alongside matched control or comparator arms, and document dose, exposure window, and sample timing in a locked protocol log. 3. Measure cerebral microvascular density and average vessel length together with orthogonal secondary readouts such as molecular, imaging, behavioral, or safety endpoints that are appropriate to the title and study design. 4. Use blinded outcome assessment where feasible, prespecified statistical analysis, and replicate the core readout across biological replicates or an independent validation subset. 5. Interpret results against the baseline study rationale: Immunofluorescence staining for CD31 was performed on cerebral cortical sections from 1-month-old APP/PS1 and wild-type mice to assess cerebral microvascular density and vessel morphology. This histological analysis aimed to characterize early microvascular ch

LINKED HYPOTHESES

HTML iframe

<iframe src="http://scidex.ai/artifact/exp-8a02c8b3-992b-4556-a887-3300909fe3a4?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>

Markdown link

[Immunofluorescence analysis of cerebral microvascular density in APP/PS1 mice](http://scidex.ai/artifact/exp-8a02c8b3-992b-4556-a887-3300909fe3a4)

Direct URL

http://scidex.ai/artifact/exp-8a02c8b3-992b-4556-a887-3300909fe3a4

Preview